CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line
FI℞ST® – Mouthwash BLM 4oz and FI℞ST® – Mouthwash BLM 6oz Unit-of-Use compounding kit provides prescription flexibility
Woburn, Mass., December 21, 2011 – CutisPharma, Inc. announced the introduction of FI℞ST® – Mouthwash BLM 4oz and FI℞ST® – Mouthwash BLM 6oz compounding kits. These products expand the FI℞ST® Magic Mouthwash line for CutisPharma. The product line already includes FI℞ST® – Mouthwash BLM 8oz, Duke’s Mouthwash, Mary’s Mouthwash and BXN Mouthwash. The active ingredients in FI℞ST® – Mouthwash BLM are comparable to those found in the most routinely prepared formulation of Magic Mouthwash containing Benadryl®, lidocaine, and Maalox®. The kits are made for one patient and include pre-weighed powders, and a pre-measured suspension. With FI℞ST® – Mouthwash Kits, the pharmacist needs only to add the powders to the liquid suspension, shake, and then dispense to the patient.
“Pharmacies have told CutisPharma, and our research has indicated that there are just as many 4oz and 6oz prescriptions for “Magic Mouthwash” containing Benadryl®, lidocaine, and Maalox® as there are for 8oz prescriptions. By launching FI℞ST® – Mouthwash BLM 4oz and 6oz, pharmacists now have greater flexibility in filling FI℞ST® “Magic Mouthwash” prescriptions.” said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. “The Company now has a wide range of FI℞ST® “Magic Mouthwash” formulations to choose from, particularly for the most commonly prescribed and used.”
FI℞ST® products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FI℞ST® Mouthwash kits, the pharmacist can compound a prescription faster than those prepared in the conventional way. A single NDC number assigned for the entire Kit facilitates the third party reimbursement process, and reduces audit- related adjustments.
CutisPharma now has fourteen proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and six Magic Mouthwash kits. Several more compounding kits are in the planning stages. FI℞ST® Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>.
The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through “compounding,” a means by which a pharmacist prepares a customized medication according to a doctor’s prescription to meet an individual patient’s medical need. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.
CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FI℞ST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Three U.S. patents have been issued to the Company with several additional patents pending.
V.P. Business Development